Contineum Therapeutics, Inc. (CTNM) Free cash flow 2023–2025
Contineum Therapeutics, Inc. (CTNM) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$55.5MFY2025 · since FY2023: $18.9M → -$55.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$55.5M | -66.5% |
| FY2024 | -$33.4M | -276.2% |
| FY2023 | $18.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTNM financial trends
CTNM RevenueCTNM Net incomeCTNM Net marginCTNM Gross profitCTNM Gross marginCTNM Operating incomeCTNM Operating marginCTNM Operating cash flowCTNM Capital expendituresCTNM Return on equityCTNM Stock buybacksCTNM Dividends paidCTNM Total assetsCTNM Total liabilitiesCTNM Shareholders’ equityCTNM overview →